Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is on recovery track with 416.67% gain from a 1-year low price of $1.50. The company added 21.09% to attain the price of $7.75 on 01/22/2018. Throughout the recent session, the prices were hovering between $6.65 and $8.05. These shares are 67.74% off its target price of $13 and the current market capitalization stands at $581.1M. The recent change has given its price a 132.87% lead over SMA 50 and 19.69% lead over its 52-week high. The stock witnessed 109.46% gains, 210% gains and 278.05% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SRNE’s volatility during a week at 11.88% and during a month it has been found around 13.29%.Sorrento Therapeutics, Inc. (SRNE) Top Holders
Institutional investors currently hold around $63 million or 13.1% in SRNE stock. Look at its top three institutional owners. Wildcat Capital Management, Llc owns $17.92 million in Sorrento Therapeutics, Inc., which represents roughly 3.08% of the company’s market cap and approximately 28.44% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 2,184,065 shares of the stock are valued at $13.98 million. The third largest holder is Intellectus Partners, Llc, which currently holds $9.87 million worth of this stock and that ownership represents nearly 1.7% of its market capitalization.
At the end of 09/30/2017 reporting period, 15 institutional holders increased their position in Sorrento Therapeutics, Inc. (NASDAQ:SRNE) by some 1,063,096 shares, 30 decreased positions by 3,617,596 and 6 held positions by 5,191,787. That puts total institutional holdings at 9,872,479 shares, according to SEC filings. The stock grabbed 6 new institutional investments totaling 239,454 shares while 14 institutional investors sold out their entire positions totaling 2,644,114 shares.Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Insider Trades
Multiple company employees have indulged in significant insider trading. Sorrento Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Shah Jaisim has acquired 10,002 shares of Sorrento Therapeutics, Inc. (SRNE) in trading session dated Jun. 15, 2017. These shares are worth $17,904 and were traded at $1.79 each. The SEC filing shows that Ji Henry performed a purchase of 29,001 shares. The President and CEO added these shares by way of transaction on Jun. 15, 2017. The company’s shares were assimilated at $1.81 per share worth to an investment of some $52,492 on account of Ji Henry.
10% Owner, Abg Management Ltd, purchased 550,000 common shares of Sorrento Therapeutics, Inc. (SRNE) in the open market. In a transaction dated Apr. 19, 2017, the shares were bought at an average price of $2, giving away a sum of $1,100,000. After this purchase, 8,132,536 common shares of SRNE are directly owned by the insider, with total stake valued at $63,027,154.
In the transaction dated Apr. 19, 2017, the great number of shares acquired came courtesy the President and CEO; Ji Henry added a total of 100,000 shares at an average price of $2, amounting to approximately $200,000. The insider now directly owns 2,260,869 shares worth $17,521,735.Sorrento Therapeutics, Inc. (SRNE) Analyst Guide
Not many analysts have released their opinion on Sorrento Therapeutics, Inc. (NASDAQ:SRNE), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.